Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Kidney Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Cisplatin 3pembrolizumab 2amminedichloro(2-methylpyridine)platinum(II) 2Nivolumab 2Cytoreduction Surgical Procedures 2trastuzumab deruxtecan 1trametinib 1sodium thiosulfate 1pertuzumab 1pazopanib 1osimertinib 1motexafin gadolinium 1fludarabine 1danvatirsen 1dabrafenib 1cobimetinib 1cemiplimab 1alectinib 1aldesleukin 1X-Rays 1Ritonavir 1Remote Patient Monitoring 1Patient-Specific Modeling 1Pafolacianine 1Oxaliplatin 1Observation 1Mitomycin 1Microscopy, Electron 1Itraconazole 1Hyperthermic Intraperitoneal Chemotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Neoplasms × motexafin gadolinium × Gynecologic × Clear all
NCT00120939 2009-04-03

Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer

Pharmacyclics LLC.

Phase 1 Completed
25 enrolled
BreastCNSGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Recurrence, Stomach Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡